US FDA finds Granules India's Gagillapur facility okay
The US drug regulator had inspected Gagillapur facility (near Hyderabad) last week and the inspection concluded with no observations, says the company
 "US FDA finds Granules India's Gagillapur facility okay")
The US Food and Drug Administration (US FDA), which inspected its Granules India’s Gagillapur manufacturing facility near Hyderabad, did not find any deviation from good manufacturing norms, according to the company.
“US FDA had inspected Gagillapur facility last week and the inspection concluded with no observations,” Granules India said in a BSE filing. The inspection was triggered by one of the applicant’s Abbreviated New Drug Application (ANDA) filing, it added.
The company manufactures pharmaceutical formulation intermediates (PFIs) and finished dosages at its Gagillapur facility.
“US FDA had inspected Gagillapur facility last week and the inspection concluded with no observations,” Granules India said in a BSE filing. The inspection was triggered by one of the applicant’s Abbreviated New Drug Application (ANDA) filing, it added.
The company manufactures pharmaceutical formulation intermediates (PFIs) and finished dosages at its Gagillapur facility.